Referral criteria
| Category A Local Expertise | Category B Clinical review, advice and guidance from MMC | Category C Care led by MMC (UCLH unless stated otherwise) |
|---|---|---|
| Uncomplicated* rheumatoid arthritis | Rheumatological disease requiring biologic therapy | Active lupus nephritis (see Kidney Pathway) (RFH) |
| Uncomplicated* seronegative arthritis: • Ankylosing spondylitis • Psoriatic arthritis • Reactive arthritis • IBD related arthritis | Rheumatological not controlled on current treatment | Large and medium vessel vasculitis |
| Uncomplicated* connective tissue disease: • Lupus • Scleroderma (restricted disease) • Sjogren’s | Rheumatological disease with restrictive lung disease and FVC >50% (see | Rheumatological disease with restrictive lung disease and FVC ≤50% |
| Osteoarthritis | Rheumatological disease with kidney involvement (see Kidney Pathway) | New small vessel vasculitis or small vessel vasculitis on immunosuppression |
| Obstetric antiphospholipid syndrome (see Haematology Pathway) | Thrombotic antiphospholipid syndrome (see Haematology Pathway) | Vascular Ehlers Danlos |
| Hypermobile Ehlers Danlos (type III) | Other Ehlers Danlos syndromes** | Scleroderma renal crisis (Royal Free) |
| Diffuse scleroderma | Antisynthetase syndrome | |
| Small vessel vasculitis in remission, no longer on treatment | ||
| Polymyositis-dermatomyositis | ||
| Behcet’s syndrome*** |